HomeAI · summaries
Storia in 2 fonti
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the mark | Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market since the FDA granted it accelerated approval in 2021.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease…
- ·
endpoints.news
ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial.
- ·
ADC Therapeutics' shares plummet after patient deaths in trial of Zynlonta
Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which…